Autologous Ex Vivo Lentiviral Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I Provides Sustained Efficacy with a Favorable Safety Profile
Rattachement africain : gb, es, us, de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background Severe leukocyte adhesion deficiency-I (LAD-I) results from biallelic deleterious ITGB2 variants leading to deficient/defective CD18 leukocyte expression and impaired endothelial adhesion and extravasation. Children with <2% of normal CD18 neutrophil expression experience recurrent, life-threatening bacterial and fungal infections, and extensive mortality. Allogeneic hematopoietic stem cell transplantation (alloHSCT) is potentially curative but limited by donor availability, graft-versus-host disease (GvHD), and graft failure (GF). Aims To evaluate the long-term safety and efficacy of RP-L201 (marnetegragene autotemcel), an autologous CD34+ hematopoietic stem cell gene therapy utilizing the Chim-CD18-WPRE lentiviral vector carrying ITGB2, including restoration of peripheral blood (PB) polymorphonuclear cell (PMN) CD18 and CD11 expression. Methods Patients ≥3 months old with severe LAD-I enrolled in the pivotal phase I/II study (NCT03812263), underwent G-CSF/plerixafor mobilization, apheresis, ex vivo transduction of CD34+ cells with RP-L201, and myeloablative busulfan (cAUC 71.6mg/L*h) conditioning, including therapeutic drug monitoring prior to infusion. Assessments included alloHSCT-free survival, PB PMN CD18 expression, PB vector copy number (VCN) and integration site analysis (ISA), leukocytosis normalization, and infection-related hospitalization annualized events. All patients subsequently entered the long-term follow-up (LTFU) study (NCT06282432). Results As of June 18, 2025, nine patients (age at infusion 9.8–117.4 months) were treated and followed for a median (range) of 50.92 (42.6–67.9) months. AlloHSCT-free survival is 100% with no GF. VCN was 0.42–2.4 at 3 months post-infusion and remained durable thereafter with a mean VCN of 1.73 at M12, sustained through M24 and beyond with concomitant sustained PMN CD18 expression. There were no new skin or oral lesions from the end of the parent study to the data-cut date in the LTFU study. Significant infections (either requiring IV antimicrobials or hospitalization) were markedly (90.7%) reduced from pre-infusion through the following 91 days post-engraftment up to the end of the study. RP-L201 was well-tolerated with no discontinuations or RP-L201-related adverse events. ISA demonstrated highly polyclonal integration patterns without evidence of predominant clones. Summary/Conclusion Treatment with RP-L201 results in durable phenotypic correction across all relevant clinical and laboratory parameters of severe LAD-I patients. The long-term benefit-risk profile for RP-L201 remains favorable, with no RP-L201-related adverse events and 100% alloHSCT-free survival.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Autologous Ex Vivo Lentiviral Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I Provides Sustained Efficacy with a Favorable Safety Profile
- Date Crossref
- 01/05/2026
- Éditeur
- Rockefeller University Press
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Great Ormond Street Hospital pays non établi dans la noticeÉtablissement de santé
-
Great Ormond Street Hospital for Children NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
University College London pays non établi dans la noticeUniversité ou école supérieure
-
Hospital Infantil Universitario Niño Jesús Fundacion para la investigacion Biomedica pays non établi dans la noticeÉtablissement de santé
-
Centro de Investigación Biomédica en Red pays non établi dans la noticeStructure de recherche
-
Instituto de Investigación de Enfermedades Raras pays non établi dans la noticeStructure de recherche
-
Hospital Universitario Fundación Jiménez Díaz pays non établi dans la noticeÉtablissement de santé
-
Eternity Bioscience (United States) pays non établi dans la noticeEntreprise
-
Centro de Investigaciones Energéticas pays non établi dans la noticeStructure de recherche
-
University of California pays non établi dans la noticeUniversité ou école supérieure
-
University of San Francisco pays non établi dans la noticeUniversité ou école supérieure
-
Medizinische Hochschule Hannover pays non établi dans la noticeUniversité ou école supérieure
Great Ormond Street Hospital, Great Ormond Street Hospital for Children NHS Foundation Trust et University College London, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.